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Abstract
We examine the HIV eradication in this paper using a mathematical model and analyse the oc-
currence of virus eradication during the early stage of infection. To this end we use a deterministic
HIV infection model, modify it to describe the pharmacological dynamics of antiretroviral HIV drugs,
and consider the clinical experimental results of preexposure prophylaxis HIV treatment. We also use
numerical simulation to the model the experimental scenario, thereby supporting the clinical results with
a model-based explanation. The study results indicate that the protocol employed in the experiment can
eradicate HIV in infected patients at the early stage of the infection.
I. INTRODUCTION
Human immunodeficiency virus (HIV) is a retrovirus to cause acquired immune deficiency
syndrome (AIDS) [1]. HIV infection can cause the virus to infect CD4 T-cells and macrophages.
A CD4 T-cell infected by HIV stops performing the role in the human body’s immune system
and instead produces new copies of the HIV virus. Once the CD4 T-cell count reaches a certain
minimum, the immune system cannot work reliably. Although HIV drug treatment has advanced,
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2AIDS continues to be a prevalent worldwide disease. For example, in 2009, 1.8 million patients
died from AIDS and the total number of HIV infected patients was estimated to be 33.3 million
[2].
A number of studies based on mathematical models have been published to better understand
the dynamics of HIV infection. For example, several HIV/AIDS mathematical models have
been reported in [3]–[7]. In [8]–[10] the authors have presented control systems applications for
these HIV models. We investigate HIV eradication in this paper using a mathematical model
and consider the clinical experiments reported in [11], which has been primarily presented to
evaluate the physical effect of preexposure antiretroviral chemoprophylaxis in the prevention of
HIV infection.
Preexposure antiretroviral chemoprophylaxis is regarded as a promising approach to prevent
HIV infection [12]–[14]. Currently preexposure prophylaxis is rarely used for men and transgen-
der women. However, if evidence of the effectiveness and safety becomes available, most could
consider its use. In order to examine the clinical effect of preexposure prophylaxis for men and
transgender women, experiments have been designed and conducted [11].
In the experiments conducted in [11], 2499 randomly assigned uninfected people received
either a placebo or FTC-TDF, i.e., a combination of emtricitabine and tenofovir disoproxil
fumarate, once a day. The experimenters followed the studied subjects for 3324 person-years.
At the enrollment, 10 of the subjects were found to have been HIV-infected. During follow-up,
100 of the subjects became HIV-infected and of these, 64 were in the placebo group and 36
were in the FTC-TDF group. This result indicates a 44% reduction in HIV infection. Therefore
the experimenters concluded that the drug FTC-TDF could prevent HIV infection in the studied
subjects. For detailed information regarding the experimental data and results, see [11].
To theoretically study the experimental results we employ the extracellular deterministic HIV
model used in [3], [4] and modify the model with the pharmacological dynamics studied in
[15], [16]. Using this modified model we analyse the possibility of virus extinction in the HIV
treatment of preexposure chemoprophylaxis and the results of the study are supported by the
experiment results of [11]. In addition our research can theoretically explain the experimental
results, based on the modified mathematical model.
Preliminary work relating to that in this paper has been presented in [17]. The research pre-
sented here extends our investigation of the virus eradication criterion to preexposure prophylaxis
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3HIV treatment and its corresponding parameter conditions.
The main contribution of this research can be summarised as follows. We prove that our
HIV infection model extended with pharmacological dynamics is realistically consistent with
the results of the experiments in [11]. Particularly our mathematical model simulation study
results imply that the experimental protocol eradicates the virus under some specific subject
conditions.
The effect of the experiment in [11] on the cellular immune response has been studied in
[18]. In contrast with [18], the mathematical model used in this paper considers no term related
to immune system enhancement. The focus of this paper is on HIV eradication during the early
stage of the virus infection, when no immune response or cellular latent reservoirs of HIV can be
established. Based on the same reasoning, we do not model the latent HIV reservoirs, which are
the main reason that HIV eradication is impossible in the later stage of virus infection [19]. It is
notable that the experiment in [11] was intended to address HIV preexposure prophylaxis, i.e.,
drug treatment (and prevention of infection) immediately before or after the contact with HIV. If
this treatment works effectively, then the infection remains at the early infection stage, preventing
further infection and suppressing the virus load to a sufficiently low level. Note that preexposure
and postexposure prophylaxis for HIV have been studied by stochastic HIV eradication analysis
in [20]–[22].
We organise this paper as follows. Section II introduces the HIV infection model of [3], [4],
which we extend to include pharmacological dynamics to numerically simulate the experiments
in [11]. In section III we describe the simulation studies performed with the modified model of
HIV infection. In section IV we discuss our results and draw our conclusions.
II. HIV DYNAMIC MODEL INCLUDING PHARMACOLOGICAL DYNAMICS
In this section we describe our extension of the HIV model used in [3], [4] to include the
pharmacological dynamics of FTC-TDF.
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4A. Three-dimensional HIV Dynamics
The model of [3], [4] is as follows:
x˙ = λ− dx− βxv,
y˙ = βxv − ay,
v˙ = ky − cv.
(1)
Note that the states, x, y, and v, are the concentrations of specific cells. That is, x, y, and v
describe the concentrations of healthy CD4 T-cells (CD4/mm3), CD4 T-cells infected by HIV
(CD4/mm3), and virions (RNA copies/ml), respectively.
In order to model the drug effect on β, we introduce η, 0 ≤ η ≤ 1, presenting to the drug
efficacy, to be the control input. Then the parameter β is given by:
β = (1− η)β¯. (2)
From a control systems perspective, the control input η corresponds particularly to the efficiency
of reverse transcriptase inhibitors (RTIs). It is notable that FTC and TDF are classified in this
category of antiretroviral drugs. The value η = 1 implies a perfect HIV infection block by the
drug, whereas η = 0 implies there being no effect by the drug. In subsection II-B we further
model the control input η to describe the effect by the drug FTC-TDF. For additional details on
the model see [3], [4].
As stated above, compared to the research in [18], the mathematical model (1) in this paper
does not consider the immune response. It is notable that the experiments of [11] were intended
for HIV preexposure chemoprophylaxis, which sought virus extinction during the early stage
of HIV infection, thus any boost in the immune response was neglected. Practically, such an
approach (i.e., with no suppression effect by the immune response considered) can produce
more conservative results regarding HIV eradication, because the immune response always acts
suppressing the virus and the infected cells. For the same reason, model (1) does not consider
terms related to a latent HIV reservoir. As long as the treatment works properly and the infection
is prevented, we assume that the infection process remains at the early stage, with no immune
response or development of any latent virus reservoir.
The parameters of model (1) are positive, as estimated in [9] on the basis of clinical data. Table
I provides the model’s median parameter values. For additional studies on parameter estimation
for HIV models see [23]–[25] and the references therein.
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5TABLE I
ESTIMATED VALUES OF HIV MODEL PARAMETERS [9]
Parameter Median Value Parameter Median Value
λ 5.36 mm−3 / day d 0.012 / day
β 8.38 × 10−8 ml / day a 0.041 / day
k 6.85 mm3 ml−1 / day c 0.280 / day
The parameter estimation in [9] has been performed during HIV drug treatment. As such,
Table I suggests that the estimated value of β has been associated with full medication, rather
than the value of β¯. Meanwhile the parameter estimations in [10] have been made based on the
pretreatment and posttreatment data of six volunteer patients. From the study in [10], based on
the pretreatment data, the β¯ median value is estimated to be 9.34× 10−7 (ml / day).
Table I presents the estimated value of λ for HIV-infected patients. In general the CD4 T-
cell count for HIV-free subjects is known to be approximately 1000/mm3 [3]. Therefore it is
generally assumed that the median value of λ for uninfected individuals is 12, i.e., d × 1000.
B. Pharmacological Dynamics for FTC-TDF
Currently most control schemes for the HIV drug treatment, e.g., the schemes of the studies
in [26]–[28], cannot be applied to HIV-infected patients. This is because the widely considered
control input for HIV models is the efficacy of the drug in the human body, not the drug dosage.
The efficacy of the drug, which ranges between zero and one, is not accurately described by the
drug amount.
Now we investigate the relationship between the control input of model (1) and the HIV
drug dose with additional pharmacokinetic and pharmacodynamic modeling. By doing so we
obtain an extended model that uses the drug dosage as the control input, which is more practical
than previous models for biomedical applications. It is notable that different HIV infection
models have been employed to research the relationship between the virus dynamics and the
concentration of HIV drugs [18], [29]–[31]. In particular an extended HIV infection model has
been presented in [18] based on the HIV infection model with immune response modeling of
[6], [28].
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6The drug administration process into the human body has two phases [15]. The first is the
pharmacokinetic phase, corresponding to the profiles of the drug level and time, and involves the
drug dose, administration route, and intake frequency. The second phase is the pharmacodynamic
phase, corresponding to the effects realised by the drug. The results of this phase depend on the
concentration of the drug in the action compartments.
1) Pharmacological Dynamics Modeling: Typically drugs are prescribed to be taken at a
constant interval and at a constant dose. In this research we assume that the drug is absorbed
instantaneously and completely, is distributed in the human body as one compartment, and is
eliminated by first-order kinetics. The elimination rates of FTC and TDF are modelled by:
σ˙F = −kFσF , (3)
σ˙T = −kTσT . (4)
σF and σT are the intracellular amounts of FTC and TDF, respectively. kF and kT are the constant
rates of elimination of the first-order FTC and TDF, respectively. Note that these elimination
rates are related to the drug half-life intracellularly. For example the half-life of FTC, tF 12 , is
log 2/kF . The HIV-drug intake can be regarded to be an impulsive control input.
A number of studies have empirically fit dose-response curves [16]. The Hill function is one






η(t) corresponds to the drug efficiency response by the drug plasma concentration C(t). γ and
Q are constants, and ηmax is the maximum response level.
As in [16] we let Q = 1/C50. The parameter C50 is the drug plasma concentration reducing
the drug efficiency to 50% of ηmax. As in [32]–[34] we assume that γ = 1 since the drug
considered in this paper is a combination of FTC and TDF, which are classified as nucleoside
reverse transcriptase inhibitor (NRTI). Note that in this subsection we consider the human body
to be one-compartment.
At time t we obtain the drug amount in the human body as the product of the plasma
concentration (C(t)), the human body mass (M), and the apparent volume of distribution (Vd).






where σ(t) = C(t)VdM and σ50 = C50VdM . For an additional description of the pharmacological
dynamic model, see [10].
2) Pharmacological model parameters: In this paper we consider FTC-TDF as it has been
employed in [11]. One tablet of FTC-TDF contains a total of 500 mg, combining with 200 mg
of FTC and 300 mg of TDF. This tablet is also known by the brand name Truvada R© [35]. To
describe the simultaneous effects of FTC and TDF we exploit two pharmacological models.
We consider the representative pharmacological parameters to be kF = 0.0178 /h i.e., 0.4266
/day, kT = 0.0042 /h i.e., 0.1014 /day, σ50,F = 0.6762 mg, and σ50,T = 20.5744 mg. Note that
the subscript F stands for FTC whilst the subscript T stands for TDF. For a study involving the
detailed estimation of these parameters, see [18].
While here we suggest representative values of the pharmacological parameters, in subsection
III-B we consider a range of parameters.
C. Integration of Models with Control Input
Model (1) including (2) is now combined with (3) and (6), to yield:
x˙ = λ− dx− (1− ηF ) (1− ηT ) β¯xv,
y˙ = (1− ηF ) (1− ηT ) β¯xv − ay,
v˙ = ky − cv,
σ˙F = −kFσF ,











Note that we assume that the drug effects by FTC and TDF are totally independent of each
other.
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8Now we set X(t) := [x(t) y(t) v(t) σF (t) σT (t)]T . Then we represent model (7) by the
following:
X˙ = F (X). (8)
Using model (8) we can simulate the experiment of [11]. To this end we use the impulsive
control inputs in model (8) to describe the drug intake and the HIV exposure for the protocol of
the experiment. These can be approximately modeled by the instantaneous changes in σF , σT ,
and v, respectively. We also assume that at an instance of discrete time the drug is administrated.
HIV drugs are generally delivered as extended release formulations [36], while the drug intake
is treated as an impulsive input in the HIV model.
Although in [37] an impulsive control input has been modelled as Dirac-delta-function on X˙ ,
here we exploit the equivalent description of a hybrid system. The system is described with a
discontinuity on X , given by:
X˙(t) = F (X(t)), if t /∈ Sd ∪ Sv,
X+ = X + Vd, if t ∈ Sd,
X+ = X + Vv, if t ∈ Sv,
(9)
where Vd and Vv are the vectors describing the instantaneous changes in the medicine states
(i.e., σF and σT ) and for the virus state v, respectively. Note that Sd is the set, at each element
of which the instantaneous changes occur on the states σF and σT while Sv is the set, at each
element of which the instantaneous changes occur on the state v.
With respect to the instantaneous changes of σF and σT we consider the oral bioavailability
for Vd. Oral bioavailability is a pharmacokinetic parameter used to describe the fraction of an
oral dose reaching the system, namely:
Vd = [0 0 0 200(mg)×BF 300(mg)×BT ]
T . (10)
The bioavailability of FTC is BF while the bioavailability of TDF is BT . The median values of
BF and BT are 0.92 and 0.25, respectively [38]. Additionally it is assumed that if a fraction of
the administered drug reaches the system, then it is completely converted into the intracellular
activation form.
Following the experimental protocol of [11], we set Sd := {1, 2, 3, 4, · · · , Td}, where the
treatment period Td is 450 (days). It is assumed that the contacts with HIV occur at instants,
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9that are the elements of the set Sv. In a later section we determine the Mv value of Vv = [0 0
Mv 0 0]T .
D. Consideration of the Virus Eradication Cases
As model (1) is deterministic and continuous-time, it is impossible for the state v (or the
infected CD4 T-cell y) to be reduced to 0 [4], [39]. It is notable that viruses and cells are
countable objects in biological systems, whereas the state variables of the model (1) are positive
real.
In this paper it can be assumed that HIV is eradicated if the HIV and infected CD4 T-cells are
reduced to sufficiently low levels, because we consider preexposure prophylaxis HIV treatment,
not need to consider latent HIV reservoir. In [4], [39], for example, the elimination of HIV has
been discussed with a threshold corresponding to a virus population of less than 1 particle. Thus,
to study virus extinction in an HIV patient in this simulation study, threshold conditions for the
virus and infected CD4 T-cells are required. To this end we consider the following criterion as
characterising the virus eradication.
Virus Eradication Criterion for Preexposure Prophylaxis HIV Treatment (VEC PrEP)
In the model (1) the virus is considered to be eradicated during the experimental protocol if
there exists a time instant T (Tm ≤ T ≤ Td) such that kyy(T ) < 0.5 and kvv(T ) < 0.5, where
ky = 5 × 10
6
, kv = 5 × 10
3
, and Tm = max(Sv). Otherwise the virus is not considered to be
eradicated.
Note that in this work we consider the total volume of human blood i.e., 5,000 ml, instead of the
extracellular fluid volume, considered in [40]. Then kyy(·) and kvv(·) are the subject’s infected
CD4 T-cells count and the HIV virion count.
We assume that the virus eradication case, based on the VEC PrEP, corresponds to the HIV
prevention cases of the experiment performed in [11]. The assumption is reasonable because
we consider only the early HIV infection stage and not the immune response or cellular latent
HIV reservoirs. Note that the preexposure prophylaxis HIV treatment given in the experiment
of [11] can prevent infection, suppress the viral load, and keep the infection at the early stage.
For the later stage of HIV infection, this approximation would not be reasonable due to the
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presence of latent HIV reservoirs, which are not considered in model (1), and would result in
HIV persistence. For studies similar to our research based on the stochastic analysis of HIV
eradication during the early stage of HIV infection, see [20], [21].
Remark 1: In the absence of drug treatment the HIV-free equilibrium point (λ/d, 0, 0) of
model (1) with the given parameter set of Table I is unstable [3], [4]. However, by applying
the VEC PrEP, the equilibrium point becomes locally stable because the states y and v are
considered to be zero when y < 0.5/ky and v < 0.5/kv, respectively. The basin of attraction of
the point is computed to be: x > 0, y < 0.5/ky, and v < 0.5/kv.
In [41] the stability of the HIV-free equilibrium point of the HIV model when using periodic
multidrug therapy has been analysed with the so-called basic reproduction number. Compared
with [41] this paper deals with virus eradication during drug treatment, rather than whether or
not the virus increases during treatment. Note that even in cases in which the virus decreases
by drug therapy the VEC PrEP can remain unsatisfied for Tm ≤ T ≤ Td.
Even with the VEC PrEP and a stable equilibrium point (i.e., HIV-free status), this does not
necessarily imply that we can control the state rendered into the point’s basin of attraction. In
the following section we investigate this possibility based on the experiment protocol of [11]
and the parameters of model (7).
III. NUMERICAL SIMULATIONS
For the simulations of this paper the initial condition is considered to be X(0) = [1000 0 0
0 0]T corresponding to HIV-free status, since the normal CD4 T-cell count of HIV uninfected
subjects is approximately 1000 /mm3 [3].
It is assumed that Sv = {10, 50} which implies that contacts with the virus occur on the
10th and 50th days. Also it is assumed that Mv = 0.002 implying that a small number of the
HIV virions are infused into the human body. Note that this value, Mv = 0.002, corresponds
to 10 virion particles in the 5,000 (ml), total blood volume of one patient. By the experimental
protocol, max(Sv) < Td, which implies that the contacts with the virus occur during the FTC-
TDF administration days.
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A. Three Cases with Different Values of ηmax,F and ηmax,T
Since drug-resistant HIV species for the 2 NRTIs (i.e., FTC and TDF) are ideally assumed
not to exist in the patient, we can set ηmax,F = 1 and ηmax,T = 1 (see [32]–[34]). Nevertheless
antiretroviral HIV drug treatment does not succeed frequently because of the emergence of a
resistant virus [4]. This resistant emergence is often owing to the preexistence of resistant HIV
[42].
Although we can reasonably assume ηmax,F and ηmax,T to be equal to 1 because FTC and TDF
are recognised as effective antiretroviral HIV drugs [32]–[34], the emergence of drug resistant
HIV can result in reduced drug efficiency. Thus in this section we consider variations in the
values of ηmax,F and ηmax,T to demonstrate the effect of HIV resistance on HIV treatment. We
present three scenarios with three different pairs of parameter values, for ηmax,F and ηmax,T .
In the first scenario we assume that both ηmax,F and ηmax,T are equal to 0.9. Fig.1 depicts
the computer simulation results following the experimental protocol of [11]. We employ the
integrated system (9) and the parameter values for kF , kT , σ50,F , and σ50,T that are provided in
subsection II-B. The upper two graphs of Fig.1 show the time histories of ηF and ηT , respectively.
Note that the time scales of these two graphs differ from the lower three.
This simulation shows that the y and v states continuously converge to 0. Using the VEC PrEP,
HIV is eradicated in the simulation of Fig.1. For example, at Day 450, kyy(450) = 4.2567 ×
10−6 < 0.5 and kvv(450) = 7.3357× 10−6 < 0.5.
In the second scenario we assume that both ηmax,F and ηmax,T are equal to 0.8. Fig.2 presents
the result of the computer simulation. In the upper two graphs of Fig.2, note that the time scales
also differ from those of the lower three. In the simulation in Fig.2, the states v and y do not
converge to 0. Instead the states continue to increase in the latter part of the simulation. However,
based on the VEC PrEP one can conclude that HIV is eradicated in the simulation of Fig.2. For
example, at Day 250, kyy(250) = 0.0549 < 0.5 and kvv(250) = 0.0492 < 0.5.
Note that we apply the VEC PrEP to the data from the simulation results, once the simulation
is completed. Then we determine whether there exists any time instant in which the condition
of the VEC PrEP is satisfied during the entire simulation period. As such, any virus rebound in
the latter part of the simulation is irrelevant to the conclusion based on the VEC PrEP.
For the third simulation we set both ηmax,F and ηmax,T to be equal to 0.7. Fig.3 presents
the result of computer simulation. Note that the lower three time scales in this figure differ
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Fig. 1. Computer simulation results following the protocol of the experiment in [11] using model (8) with ηmax,F = 0.9 and
ηmax,T = 0.9. The simulation employs Sv = {10, 50} and Mv = 0.002 to implement the impulsive change of the virus. Note
that the time scale of the upper two graphs, in which the time histories of ηF and ηT are represented, respectively, differ from
the lower three. Also note the third graph shows the time history of x− x(0) rather than x, because the x state remains close
to x(0).
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Fig. 2. Computer simulation results of the protocol of the experiment in [11] using model (8) with ηmax,F = 0.8 and ηmax,T
= 0.8. The simulation employs Mv = 0.002 and Sv = {10, 50} to describe the impulsive virus infusion. The time scale of the
upper two graphs differ from the lower three. The third graph shows the time history of x− x(0) rather than x.
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Fig. 3. Computer simulation results of the protocol of the experiment in [11] using model (8) with ηmax,F = 0.7 and ηmax,T
= 0.7. Note that the lower three time scales differ from those in the other figures. We employ Mv = 0.002 and Sv = {10, 50}
in this simulation.
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Fig. 4. Three-dimensional plot with ηmax,F , ηmax,T , and ωm where ωm = kv minTm≤t≤Td v(t). The figure is based on the
simulation results in the (ηmax,F , ηmax,T ) parameter plane ranging between 0 and 1. All other system parameters are described
in subsection III-A.
from those of Fig.1 and Fig.2. In the simulation ky minTm≤t≤Td y(t) = 1.0444 > 0.5 and
kv minTm≤t≤Td v(t) = 0.6600 > 0.5. Thus the minimum cell number of the infected CD4 T-
cells and the minimum HIV virion number in the subject are both greater than 0.5 over the time
period from the occurrence of the last virus infusion to the end of the experiment. Thus, by the
VEC PrEP, HIV eradication is not achieved.
B. Parameter Plane for ηmax,F and ηmax,T
In this subsection we use a parameter plane (ηmax,F , ηmax,T ) to study the range of ηmax,F
and ηmax,T between zero and one. All other parameters are as described in subsection III-A. 31
parameter values are considered along the axis of the plane. Thus we have 31 × 31 pairs of
parameter values and we have performed simulations for each pair for 450 days, as described
in subsection III-A.









where ky = 5 × 106, kv = 5 × 103, and Tm = maxSv. Thus ψm and ωm are the minimum cell
count of the infected CD4 T-cells and the minimum HIV virion count in the subject (i.e., 5,000
ml of blood) over the time period from the occurrence of the last virus infusion to the end of
the experiment. Based on the simulation results in the (ηmax,F , ηmax,T ) parameter plane, Fig.4
shows a 3-dimensional plot with ηmax,F , ηmax,T , and ωm.
To apply the VEC PrEP, Fig.4 is not sufficient to determine whether the conditions of the
VEC PrEP are satisfied in each simulation.
Thus we plot the results in Fig.5 with circles, crosses, and dot symbols. After each simulation,
if the HIV is considered to be extinguished with reference to the VEC PrEP, then we mark the
corresponding (ηmax,F , ηmax,T ) point with a circle on the plane. As shown in the case described
in subsection III-A, the experimental protocol could lead to HIV eradication for these subjects.
If the VEC PrEP conditions are not met, we investigate how the simulation result deviated
from these conditions. If ψm ≥ 0.5 and ωm ≥ 0.5, then we mark the corresponding point with
a cross on the plane. The dot marks reflect cases in which ωm < 0.5 but ψm ≥ 0.5, i.e. those
for which the y state could be considered to generate multiple copies of HIV, resulting in HIV
persistence. Note that no other cases are identified.
IV. CONCLUSIONS
In this study we have used a mathematical model approach to investigate HIV eradication
in the early HIV-infection stage. First we have considered the clinical experimental results of
[11]. To perform computer simulation experiments we have employed the three-dimensional HIV
model of [3], [4] and we have modified it to include the pharmacology dynamics of antiretroviral
HIV drugs. We then have performed numerical simulation experiments.
In comparison with the study in [18] in the mathematical model of this study we have not
considered any immune response effect. This is because we have been only interested in the
phenomenon of HIV eradication during the early stage of the virus infection prior to any boost in
the immune response. By doing so (i.e., in the absence of any suppression effect by an immune
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Fig. 5. Simulation results in the plane of parameters, (ηmax,F , ηmax,T ), with decision by the VEC PrEP. When HIV is
considered to be extinguished based on the VEC PrEP, we mark the corresponding point with a circle on this plane. The dots
and the crosses on the plane correspond to the cases with ψm ≥ 0.5 and ωm < 0.5, and to the cases with ψm ≥ 0.5 and
ωm ≥ 0.5, respectively.
response) we have realised more conservative simulation results and parameter conditions, since
the immune term always suppresses the virus and infected cells. It is notable that the experiment
of [11] has been intended for HIV preexposure chemoprophylaxis. Eventually mathematical
model-based studies on the experiment of [11] (e.g., [18] and this paper) could help to make a
plan for further experiments.
Using the extended HIV mathematical model, We have revisited the experimental results via
the computer simulation, and our study results have provided insight for better understanding
the implications of those results. Our study result has suggested that the experimental protocol
could lead to HIV eradication during the early stage of HIV-infection. Our study also provides
some parameter conditions to achieve virus extinction by preexposure prophylaxis treatment for
HIV.
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It is notable that in July 2012 the U.S. Food and Drug Administration approved the usage of
the drug FTC-TDF for the first time as a treatment for reducing the risk of HIV infection [43].
To extend the investigation of this paper we are considering several future research directions.
In this paper we have employed the model (1) for the preexposure prophylaxis for HIV. However,
for postexposure prophylaxis for HIV, a different HIV model must be considered that describes
latent reservoirs of the virus. Latent reservoir makes it very difficult to extinguish the virus
in an infected patient by postexposure prophylaxis for HIV. Also while we have employed a
deterministic model for the HIV infection problem in this paper, stochastic models could be
considered for future investigation.
In this paper we have focused on the experiment protocol of [11], i.e., with patients taking one
tablet of FTC-TDF once a day. In the simulation studies of section III that follows the protocol,
the decision by VEC PrEP stems from the inter-patient parameters, i.e., ηmax,F and ηmax,T ,
which correspond to the patients sensitivity to the drugs. In order to satisfy the VEC PrEP we
could adjust the amount of the drug taken, rather than imposing a fixed daily dosage protocol.
For example, we might increase the amount of drug for a non-sensitive patient to eradicate the
virus. This type of study will be considered in future work.
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